Biohaven’s first-in-modality extracellular degrader BHV-1300 reduced levels of its immunoglobulin G (IgG) target by up to 43% in an ongoing phase I trial. The two-armed small molecule acts by dragging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback